Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P180002/S032

Zephyr Endobronchial Valve System

Pulmonx Corporation · Decision date Sep 11, 2026

MEDTECHLEDGER EXPLANATIONP180002/S032

What did the FDA approve?

The FDA recorded an approval decision dated 2026-09-11 for P180002/S032, a real-time process supplement from Pulmonx Corporation covering the Zephyr Endobronchial Valve System, product code NJK under anesthesiology. The listed statement describes changes to the funnel component of the Endobronchial Loader System included with the Zephyr 4.0-LP Endobronchial Valve, filed under change design/components/specifications/material. The supplement number establishes a link to the original P180002 approval; it does not approve the whole system anew.

The record gives no detail on the prior or revised funnel design, materials, or specifications, and no evidence of bench performance, safety, or clinical effectiveness beyond the stated purpose. The decision is a manufacturing process notice, not a new indication or trial result.

It is not established what specific change was made to the funnel component, what testing supported it, or whether any labeling changed.

FDA approval order statement

Approval for changes to the funnel component of the Endobronchial Loader System included with the Zephyr 4.0-LP Endobronchial Valve.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Anesthesiology
Decision date
Sep 11, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P180002/S032
Regulatory pathway
PMA supplement
Product code
NJK
Decision code
APPR
Decision date
Sep 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Valve, pulmonary.

Product code
NJK
FDA device class
3

For the original device and its historical approval scope, see PMA P180002. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P180002 · Original PMA

    Zephyr Endobronchial Valve System

  2. P180002/S032 received

    Application receipt date recorded by FDA.

  3. P180002/S032 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P180002. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P180002

Product / regulatory recordCompanyPathwayDecision dateSource
Pulmonx CorporationPMA approvalJun 29, 2018FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Pulmonx Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
700 Chesapeake Dr., Redwood City, CA, 94063

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records